¶ na = not applicable. Non-recommended treatment poses no risk. Guidelines do not recommend statin therapy for patients with a 10-year risk of ASCVD.

¶ na = not applicable. Non-recommended treatment poses no risk. Guidelines do not recommend statin therapy for patients with a 10-year risk of ASCVD.

** 10-year risk for ASCVD is categorized as: Low-risk (<5%) Borderline risk (5% to 7.4%) Intermediate risk (7.5% to 19.9%) High risk (≥20%)

Visit Summary Below is a summary of patient’s risk, treatment options, and treatment advice based on the data provided.

Treatment Advice *

LDL-C Management (for this Patient)

The counseling section can be accessed by entering the required characteristics for patients aged 40-79 years.

Blood Pressure Management (for this Patient)

Tobacco Cessation (for this Patient)

Diabetes Mellitus Management (General)

Lifestyle Recommendations (General)

Nutrition and Diet

• Consider whether lowering BP, lowering LDL-C, or both is the best approach.
  • Reduce ASCVD risk for all patients:
  • -Meats that emphasize vegetables, fruits, beans, nuts, whole grains, and fish are recommended (I, B-R). Meals with reduced cholesterol and sodium amounts would be useful (IIA, B-NR).
  • -The saturated fat is useful (IIA, B-NR) (IIA, B-NR).
  • -Intible to consuming trans fat, processed meat, purified carbohydrates, and sweet drinks as part of a good diet for the heart (IIA, B-NR).

  Exercise and Physical Activity

  • -In improvement of blood sugar control, weight loss (if necessary), and other ASCVD risk factors, a custo m-made diet plan focusing on the heart of the heart is recommended (I, a).
    • Adults should do the following to reduce ASCVD risk:
    • -Retassed counseling on a daily basis to optimize the active lifestyle (I, B-R).
    • -A participate in aerobic physical activity (or a combination of medium-strength and strength) with at least 150 minutes a week or 75 minutes a week (or a combination of medium-strength and strength). This includes an adult with type 2 diabetes (I, a).

    -Dresting behavior that tends to sit (IIB, C-LD).	tension	Mets
    example	Actions that tend to sit down	1-1, 5
    Watch a sleeping TV sitting, lying down,	light	1. 6-2. 9
    Walk slowly, cook, light housework	Middle	3. 0-5. 9
    Early walking (2, 4-4 miles / h), bicycle (5-9 mile / h), social dance, active yoga, recreation swimming	≥6	Vitality

    Obesity and Being Overweight

    • Jogging / running, cycling (10 miles / h or more), tennis (singles), swimming (wrap)
      • In the case of an adult with an excessive body and obesity
      • -ASCVD We are recommended to lose weight to improve the dangerous factor profile (I, B-R).
      • -In order to achieve and maintain weight loss, intervening in comprehensive lifestyles, including counseling and calorie restrictions, is recommended (I, B-R).
      • -It is recommended to calculate the physique index every year or more to identify an adult with an over-body and obesity to estimate weight loss (I, C-EO).

      Aspirin Use Recommendations (for this Patient)

      Immunization Practice (General)

      CDC's Standards for Adult Immunization Practice

      1. -It is appropriate to measure the peripheral diameter of the waist to identify a person with a high risk of heart metabolism (IIA, B-NR).
      2. Each clinical interview evaluates the vaccination status of all patients.
      3. We strongly recommend the vaccine necessary for the patient.
      4. Manage the necessary vaccines or introduce the vaccination provider to the patient.

      Immunization Practice (for this Patient)​

      Supporting Guideline Recommendation​

      Vaccines are obtained from patients.

      CDC’s Recommendation for Patients 65 and older​

      Pneumococcal vaccines are recommended for patients aged 65 and over and hig h-risk patients with cardiovascular diseases. (1, β).

      CDC’s Standards for Adult Immunization Practice​

      1. -It is appropriate to measure the peripheral diameter of the waist to identify a person with a high risk of heart metabolism (IIA, B-NR).
      2. Each clinical interview evaluates the vaccination status of all patients.
      3. We strongly recommend the vaccine necessary for the patient.
      4. Manage the necessary vaccines or introduce the vaccination provider to the patient.

      Therapy Safety Information (General)

      Register the vaccine received by the patient.

      • See the resource section of this app for complete prescription information.
      • Statin: Statin has a moderate evidence that does not increase the overall risk of adverse events, but some individuals may increase the risk of type 2 diabetes.
      • Hematostructive drugs: The adverse events of blood pressure hypotension therapy are not commonly reported and vary depending on the drug class.
      • The side effects of smoking smoking cessation cessation are not often reported in general, depending on the drug.

      ASCVD Risk Profile

      Aspirin: Aspirin has a high quality evidence that suggests that it can increase the risk of severe bleeding. Calidal infarction and computers to consider the great hemorrhagic risk of aspirin therapy and the potential benefits of aspirin therapy are available here.
      • The 1 0-year risk of the first ASCVD event is as follows:
      • Actual risk

      Actual risk

      Enter the treatment scenario that can be considered in the "therapeutic effect" tab and plot in the above graph.
      • *Prediction risk by the following treatment:
      • ASA = Start or continue taking aspirin
      • BP = Start, add, and strengthen blood pressure.
      • CH = Start or increase the amount to manage cholesterol.

      Inputs

      Inputs

      • Sm = at least 2 years smoking cessation
      • Gender woman

      White man	values	before	before
      stream
      ageTotal cholesterol (MG/DL)	240
      (mmol/L)Total cholesterol (MG/DL)
      (mmol/L)Total cholesterol (MG/DL)
      (mmol/L)Contracted blood pressure	98	140
      (MM HG)Contracted blood pressure	98	140
      (MM HG)
      Diabetes
      Smoker	Treatment of high blood pressure
      can be
      Treatment by aspirin

      Statin

      Note: These estimated values ​​include specific races and ethnic groups, especially Americans, some Asian Americans (South Asian), and some Hispanic Americans (Puerto Rico, etc.) Other groups, including some Asian Americans (such as East Asian) and some Hispanic Americans (such as Mexican Americans), may underestimate their lifetime risks. There is a possibility. The main application of these risk estimates is to promote a very important debate on the risk reduction by improving lifestyle, so we will continue counseling to improve lifestyle based on these results. The incorrectness introduced is small enough to justify.

      * Disclaimer Disclaimer: The results and recommendations provided by this app are intended to provide information to clinical judgment, but does not. Treatment options should be individually determined after discussions between patients and medical providers.

      The recommendation is characterized by both the recommended category (COR) and the evidence level (LOE). The recommended category shows the strength of the recommendation, such as the size and certainty of the possibilities for risks. Evidence level evaluates the quality of scientific evidence that supports intervention based on the type, quantity, and consistency of data from clinical trials and other information sources.

      The recommendation is characterized by both the recommended category (COR) and the evidence level (LOE). The recommended category shows the strength of the recommendation, such as the size and certainty of the possibilities for risks. Evidence level evaluates the quality of scientific evidence that supports intervention based on the type, quantity, and consistency of data from clinical trials and other information sources.

      • The potential impact of different treatments to reduce risk can only be calculated for patients aged 40 to 79 at the first consultation.
      • Risk evaluation

      The recommendation is characterized by both the recommended category (COR) and the evidence level (LOE). The recommended category shows the strength of the recommendation, such as the size and certainty of the possibilities for risks. Evidence level evaluates the quality of scientific evidence that supports intervention based on the type, quantity, and consistency of data from clinical trials and other information sources.

      ¶ na = not applicable. Non-recommended treatment poses no risk. Guidelines do not recommend statin therapy for patients with a 10-year risk of ASCVD.

      Resources

      Patient Resources

      Clinician Resources

      References

      • Entering the required characteristics for patients aged 40-79 can access the advice section.
      • DAS SR, EVERETT BM, Birtcher KK, Brown JM, JANUZZI JR JL JL, KALYANI RR, KOSIBOROD M, Magwire ML, Neumiller Jj, Morris Pb, Spellling Ls.
      • 2020 Expert Consensus decision passway on new treatments to reduce cardiovascular risk in patients with type 2 diabetics: reporting from the US Society of Society for Society of Heart Aids. J AM Coll Cardiol 2020; Doi: 10. 1016/jacc.
      • ARNETT DK, Blumenthal RS, Albert Ma, Buroker AB, Goldberger ZD, Hahn EJ, HimMelfarb CD, Khera A, LLOYD-JONES D, MICEVOY JW, MICHOS ED, MIEDEMA MD, Muñoz D, SM iTH sc, virani ss, Williams Ka SR, Yeboah J, Ziaeian B. 2019 ACC/ AHA Guideline for Primary Prevention of Cardiovascular Disease: Mi Guo Heart Society/ Mi Guo Heart 臓 グ グ グ ガ ガ イ ド ラ イ ン の ガ ガ J am color card 2019, 74: E177-232.
      • Grundy SM, Stone NJ, Bailey Al, Beam C, Birtcher KK, BlumenThal RS, Braun LT, De Ferranti S, Faiella-Tommasino J, Forman De, HEIDENREICH PA, HLATKY MA, J ONES DW, Lloyd-Jones D, Lopez-PAJARES N, Ndumele CE, Orringer CE, PERALTA CA, Sasen JJ, Smith SC, Sperling L, Virani SS, Yeboah J. 2018 ACC/AACVPR/ACPM/ADA/AGS/APH A/ASPC/ The NLA/PCNA guideline for the management of blood cholesterol： 米国心臓病学会（American College of Cardiology Foundation/American Federation of Clinical Practice）の报告书。 J am color card. 2018; xx: xxxx-xxxx.
      • ロ DC JR, ド イ c = ジョ ー ン ズ DM, ベネ ッ ト G, コ ー ディ s, ダゴ ス ティ ティ ティ ティ ティ ギボ R, グ リ ー ラ ン ド R, ラ ッ ク ラ ン ド DT, レヴィ D, オドネ ロビ ロビ シュワ シュワ ル ツ js R, ス ト ー ン NJ, ソ ル ン PWF. Cardiovascular リ ス ク 価 価 価 に r r 2013 ACC/ AHA ガ イ ド ラ イ ン: Mi Guo Heart Society/ Mi Guo Hexinxin Association Lianbang diagnosis and treatment of ガ イ ド ド の の の の ガ. J am color card 2014, 63: 2935-59.
      • Lloyd-jones DM, Huffman MD, Karmali Kn, Sanghavi DM, WRIGHT JS, Pelseri M, Masoudi Fa, Goff Jr. DC, Assession The Longitudinal Risks and Benefits of C Ardiovascular Preventive Therapies among Medicare Patients: An Assessment Tool, Journal of the American College of Cardiology (2016), Doi: 10. 1016/ J. JACC. 2016. 10. 018.
      • WHELTON PK, CAREY RM, Aronow WS, ET Al. 2017 ACC/AHA/ABC/AGS/AGS/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, AND MANAGE, and MANAGE MENT of High Blood Pressure in Adults. J am color card. 2017; Doi: 10. 1016/J. JACC. 2017. 11. 006
      • Lloyd-Jones D. M., Leip E. R., Larson M. O., Et Al. (2006) 50 歳 の の の の の の の さ さ の の の リ リ リ の の リ の 11 ー サ ー ショ ン 113: 791-798

      Clinician Resources

      Patient Resources

      References

      • Entering the required characteristics for patients aged 40-79 can access the advice section.
      • DAS SR, EVERETT BM, Birtcher KK, Brown JM, JANUZZI JR JL JL, KALYANI RR, KOSIBOROD M, Magwire ML, Neumiller Jj, Morris Pb, Spellling Ls.
      • Type 2 Diabetes Patients における Cardiovascular リ ス ク 軽 の ため の の の の の し し に に する する 2 2 2 2 2 2 専 専 コ ン セ ン サ ン サ ス ウェ パ パ パ パ パ パ パ パ パ パ パ パ パ: J am color card 2020; doi: 10. 1016/j. JACC.
      • ARNETT DK, Blumenthal RS, Albert Ma, Buroker AB, Goldberger ZD, Hahn EJ, HimMelfarb CD, Khera A, LLOYD-JONES D, MICEVOY JW, MICHOS ED, MIEDEMA MD, Muñoz D, SM iTH sc, virani ss, Williams Ka SR, Yeboah J, Ziaeian B. 2019 ACC/ AHA Guideline for Primary Prevention of Cardiovascular Disease: Mi Guo Heart Society/ Mi Guo Heart 臓 グ グ グ ガ ガ イ ド ラ イ ン の ガ ガ J am color card 2019, 74: E177-232.
      • Grundy SM, Stone NJ, Bailey Al, Beam C, Birtcher KK, BlumenThal RS, Braun LT, De Ferranti S, Faiella-Tommasino J, Forman De, HEIDENREICH PA, HLATKY MA, J ONES DW, Lloyd-Jones D, Lopez-PAJARES N, Ndumele CE, Oringer CE, PERALTA CA, Sasen JJ, Smith SC, Sperling L, Virani SS, Yeboah J. 2018 ACC/AACVPR/ACPM/ADA/AGS/APHA /ASPC/ NLA/PCNA Guideline for the Management of Blood Cholesterol: A Report of the American College of Cardiology Foundation/American Heart Association Task Force On Clinical P Ractice guidelines. J am color card. 2018; xx: xxxx-xxxxxx.
      • ロ DC JR, ド イ c = ジョ ー ン ズ DM, ベネ ッ ト G, コ ー ディ s, ダゴ ス ティ ティ ティ ティ ティ ギボ R, グ リ ー ラ ン ド R, ラ ッ ク ラ ン ド DT, レヴィ D, オドネ ロビ ロビ シュワ シュワ ル ツ js R, ス ト ー ン NJ, ソ ル ン PWF. Cardiovascular リ ス ク 価 価 価 に r r 2013 ACC/ AHA ガ イ ド ラ イ ン: Mi Guo Heart Society/ Mi Guo Hexinxin Association Lianbang diagnosis and treatment of ガ イ ド ド の の の の ガ. J am color card 2014, 63: 2935-59.
      • Lloyd-jones DM, Huffman MD, Karmali Kn, Sanghavi DM, WRIGHT JS, Pelseri M, Masoudi Fa, Goff Jr. DC, Assession The Longitudinal Risks and Benefits of C Ardiovascular Preventive Therapies among Medicare Patients: An Assessment Tool, Journal of the American College of Cardiology (2016), Doi: 10. 1016/ J. JACC. 2016. 10. 018.
      • WHELTON PK, CAREY RM, Aronow WS, ET Al. 2017 ACC/AHA/ABC/AGS/AGS/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, AND MANAGE, and MANAGE MENT of High Blood Pressure in Adults. J am color card. 2017; Doi: 10. 1016/J. JACC. 2017. 11. 006
      • Lloyd-Jones D. M., Leip E. R., Larson M. O., Et Al. (2006) 50 歳 の の の の の の の さ さ の の の リ リ リ の の リ の 11 ー サ ー ショ ン 113: 791-798
      Amsterdam E, Wenger N, Brindis R, et al. 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes. j Am Coll Cardiol. 2014 Dec, 64(24) e139-e228.

      Clinician Resources

      Patient Resources

      References

      • Back to resources
      • ARNETT DK, Blumenthal RS, Albert Ma, Buroker AB, Goldberger ZD, Hahn EJ, HimMelfarb CD, Khera A, LLOYD-JONES D, MICEVOY JW, MICHOS ED, MIEDEMA MD, Muñoz D, SM iTH sc, virani ss, Williams Ka SR, Yeboah J, Ziaeian B. 2019 ACC/ AHA Guideline for Primary Prevention of Cardiovascular Disease: Mi Guo Heart Society/ Mi Guo Heart 臓 グ グ グ ガ ガ イ ド ラ イ ン の ガ ガ J am color card 2019, 74: E177-232.
      • Grundy SM, Stone NJ, Bailey Al, Beam C, Birtcher KK, BlumenThal RS, Braun LT, De Ferranti S, Faiella-Tommasino J, Forman De, HEIDENREICH PA, HLATKY MA, J ONES DW, Lloyd-Jones D, Lopez-PAJARES N, Ndumele CE, Oringer CE, PERALTA CA, Sasen JJ, Smith SC, Sperling L, Virani SS, Yeboah J. 2018 ACC/AACVPR/ACPM/ADA/AGS/APHA /ASPC/ NLA/PCNA Guideline for the Management of Blood Cholesterol: A Report of the American College of Cardiology Foundation/American Heart Association Task Force On Clinical P Ractice guidelines. J am color card. 2018; xx: xxxx-xxxxxx.
      • ロ DC JR, ド イ c = ジョ ー ン ズ DM, ベネ ッ ト G, コ ー ディ s, ダゴ ス ティ ティ ティ ティ ティ ギボ R, グ リ ー ラ ン ド R, ラ ッ ク ラ ン ド DT, レヴィ D, オドネ ロビ ロビ シュワ シュワ ル ツ js R, ス ト ー ン NJ, ソ ル ン PWF. Cardiovascular リ ス ク 価 価 価 に r r 2013 ACC/ AHA ガ イ ド ラ イ ン: Mi Guo Heart Society/ Mi Guo Hexinxin Association Lianbang diagnosis and treatment of ガ イ ド ド の の の の ガ. J am color card 2014, 63: 2935-59.
      • The risk evaluation is used to determine the possibility that the patient may develop cardiovascular disease, heart attack or stroke in the future. In general, patients with high risk of cardiovascular diseases require more intensive treatment to prevent the onset of cardiovascular disease.
      Amsterdam E, Wenger N, Brindis R, et al. 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes. j Am Coll Cardiol. 2014 Dec, 64(24) e139-e228.

      Understanding My Cardiovascular Risk

      If the preventive medical program is unclear based on the calculation of the risks described above, medical providers should consider other factors such as family history and C reactive protein value. Considering such additional information should be useful for treatment planning to reduce the risk of patients' cardiovascular disease by 10 years.

      • Рас 10-ла рдео-осы забан солованых факоров иомоду кажды-6 е уацов в возас 20-79 л, еадеающ саболан. ьой оц 10-ло ра кажДые 4-6 л цобазос уосых возас 40-79 л, еадеающ саболосан. а сололан тож тыт пола дов пацов возас 20-59 сых заболан и е подвых высококок катососочоч разозозо-осососабабанан.
      • Risk estimates vary widely by gender and race. Patients with the same traditional cardiovascular risk factors, such as high blood pressure, may have different 10-year risks for cardiovascular disease depending on gender and race.
      • Once a risk assessment is performed, it is important for health care providers and patients to work together to discuss what the results mean. Patients and health care providers should consider together the risks and benefits of various treatments and lifestyle changes to reduce the risk of developing cardiovascular disease.
      • The AHA/ACC 2013 Guidelines on Lifestyle Management to Reduce Cardiovascular Risk provide recommendations for lifestyle choices in the treatment of cardiac disease based on the latest research and evidence. The guidelines focus on two important lifestyle choices that dramatically affect cardiovascular health: diet and physical activity. Here, we explain what every patient needs to know about the latest recommendations for reducing cardiovascular disease risk through diet and exercise.
      • Diet is an essential tool for lowering cholesterol and blood pressure, the two major risk factors for cardiovascular disease.
      • Patients with high cholesterol and high blood pressure should eat plenty of vegetables, fruits, and whole grains, and include low-fat dairy products, poultry, fish, legumes, non-tropical vegetable oils, and nuts in their diet. They should also limit their intake of sweets, sugary snacks, and red meat.

      Diet and Physical Activity Recommendations

      There are many dietary approaches that can help with heart health, such as the DASH diet and the USDA's Choose My Plate.

      Diet

      • Patients who need to lower their cholesterol should reduce their intake of saturated and trans fats. Ideally, only 5-6% of their daily calories should be saturated fats.
      • Patients with high blood pressure should not consume more than 2, 400 mg of sodium per day, and ideally should reduce their sodium intake to 1, 500 mg per day. However, even reducing sodium intake by just 1, 000 mg per day in their current diet can help lower blood pressure.
      • It is important to adjust the above recommendations while keeping in mind calorie requirements and personal and cultural food preferences. Dietary treatments for other diseases, such as diabetes, should also be considered. This can help you create healthy eating patterns that are realistic and sustainable.
      • Regular exercise can help lower cholesterol and blood pressure and reduce the risk of cardiovascular disease.
      • In general, adults should engage in aerobic exercise for an average of 40 minutes three to four times per week.
      • Moderate (brisk walking or jogging) to vigorous exercise (running or cycling) is recommended to lower cholesterol levels.

      Physical Activity

      • The 2013 AHA/ACC/TOS Guidelines for the Management of Overweight and Obesity in Adults reflect the latest research to outline best practices for treating obesity, which affects more than one-third of U. S. adults. These guidelines help answer questions like, "What is the best way to lose weight?" Here's what every patient should know about treating overweight and obesity:
      • Definition of Obesity Obesity is a medical condition in which excess body fat accumulates to the point that it adversely affects health. Obesity can be diagnosed using body mass index (BMI), height and weight measurements, and waist circumference. Obesity is defined as a BMI of 30 or higher. Abdominal obesity is defined as a waist circumference of 40 inches or more in men and 35 inches or more in women.
      • Benefits of Weight Loss: Obesity increases the risk of serious diseases, including cardiovascular disease, diabetes, and death, but even small weight loss can have significant health benefits. For obese adults, losing just 3 to 5 percent of their body weight can improve blood pressure and cholesterol levels and reduce the risk of cardiovascular disease and diabetes. Ideally, health care providers would recommend that obese adults lose 5 to 10 percent weight, which would provide even greater health benefits.

      Weight Management Recommendations

      Weight Loss Strategies There is no one diet or weight loss program that is optimal for all patients. In general, a comprehensive lifestyle intervention that includes reducing caloric intake and physical activity and behavioral modification according to the patient's preferences and health status is most successful in achieving sustained weight loss. In addition, weight loss interventions include frequent meetings with a health care provider and should be continued for at least one year for sustained weight loss.

      • Obesity obesity surgery can be a good option for severe obese patients to reduce the risk of health complications and improve overall health. However, obesity surgery should be performed only for the most risky patients until more evidence is obtained in this issue. According to the current guidelines, weight loss surgery is recommended only for extremely obese (BMI ≧ 40) patients or chronic health, and only BMI ≧ 35 patients.
      • The American Society of Heart Disease (ACC) and the US Heart Association (AHA) have recently formulated new criteria for the treatment of blood cholesterol. These recommendations are based on the thorough and cautious consideration of the latest hig h-quality clinical trials. These recommendations are for medical providers to provide the best treatment. This page introduces the highlights of a new medical guideline. The ultimate goal of the new cholesterol medical treatment guidelines is to reduce the risk of heart attack, stroke, and death. Therefore, not only cholesterol measurement and treatment, but also a person is already in a state of arteriosclerosis cardiovascular disease (ASCVD), or whether it may be beneficial and benefit from treatment. The emphasis is on doing.
      • Heart attacks and stroke are usually caused by arteriosclerosis cardiovascular disease (ASCVD). ASCVD develops when plaque, which contains a lot of cholesterol, accumulates. This plaque hardens over time and narrows the artery.
      • These medical guidelines include the most effective treatments to reduce blood cholesterol for the most effective people. The most important thing is that these treatments are selected as the best cholesterol reduced strategies to reduce future heart attacks and stroke risks. By sharing this information with medical workers, you can think and ask questions together.

      Blood Cholesterol Management Recommendations

      Based on the latest and complete survey of available clinical trial results:

      What is ASCVD?

      Medical providers should focus on identifying the most likely person to have a heart attack or stroke, and to be able to receive effective treatment to reduce the risk.

      Cholesterol should be considered along with other factors that are known to be more likely to cause heart attacks and stroke.

      Key Points

      Knowing the risks of myocardial infarction and stroke helps to determine if it is necessary to take statu s-related drugs to reduce the risk.

      • If drug therapy is necessary, the overwhelming evidence suggests that statins are the first choice for reducing the risk of heart attack and stroke in certain high-risk patients. For patients who cannot take statins, there are other cholesterol-lowering drugs; however, there is not much research supporting their use.
      • Your health care provider will first want to assess your ASCVD risk (assuming you are not already at risk). This information will help them determine whether your risk of heart attack or stroke is high enough that treatment is needed.
      • To do that, your health care provider will review your medical history and 2) measure your overall risk of heart attack or stroke. When they do, they will probably want to know:
      • Whether you have ever had a heart attack, stroke, or blocked arteries in your heart, neck, or legs.

      Evaluating Your Risk

      Your risk factors. In addition to your total cholesterol, LDL cholesterol, and HDL (the so-called "good") cholesterol, your health care provider will look at your age, whether you have diabetes, and whether you smoke or have high blood pressure.

      Your lifestyle habits, other medical conditions, past drug treatments, whether any family members have had high cholesterol, or if anyone had a heart attack or stroke at a young age.

      • As part of this evaluation, you will need a lipid or blood cholesterol panel. This blood test measures the amount of fatty substances (called lipids) in your blood. You may need to go for a quickie (without eating for a period of time) before getting a blood test.
      • If there is any question about your risk of ASCVD or whether medication is effective, your healthcare provider may do additional evaluations or order additional tests. These test results will help you and your healthcare team determine the best treatment for you. These tests may include:
      • Lifetime Risk Assessment - How likely you are to have a heart attack or stroke in your lifetime

      Coronary Artery Calcium Score (CAC) - A test that shows the buildup of plaque and fat in the walls of your heart arteries.

      CRP is an indicator of inflammation and inflammation in the body. High levels are associated with heart attacks and strokes.

      • Ankle Blood Pressure Index (ABI) - The ratio of blood pressure in the ankle compared to blood pressure in the arm, which can predict peripheral artery disease (PAD).
      • If your low-density lipoprotein (LDL or "BAD") cholesterol levels are very high, your health care provider may want to know if you have hereditary or familial hypercholesterolemia. Hypercholesterolemia can run in families.
      • Before a specific treatment plan is developed, your doctor will talk to you about options for lowering your blood cholesterol and reducing your risk of atherosclerotic disease. He or she will also talk to you about heart-healthy lifestyle choices and whether cholesterol-lowering medications may be effective.
      • Adopting a heart-healthy lifestyle is the first and best way to reduce your risk of problems. Doing so also helps control or prevent other risk factors (e. g., high blood pressure and diabetes). Experts recommend:

      Eat more vegetables, fruits, and whole grains. Also, eat low-fat dairy products, poultry, fish, legumes, and nuts, and limit sweets, sugary snacks, and red meat.

      Your Treatment Plan

      Exercise regularly. Ask your health care provider how often and how much exercise is right for you.

      Heart-Healthy Lifestyle

      Maintain a healthy weight.

      • Quit smoking or get help quitting.
      • Keep track of your health, risk factors, and doctor's appointments. For some people, lifestyle changes alone may not be enough to prevent heart attacks and strokes. In these cases, taking an appropriate dose of a statin may be necessary.
      • There are two types of cholesterol-lowering drugs: statins and non-statins.
      • There is a lot of evidence that statins provide the greatest benefits and have fewer safety issues. In particular, there seems to be a group of patients who benefit most from taking moderate or high-intensity medications. Based on this information, statins are recommended for the following patients:
      • ASCVD

      Medications

      Very high LDL cholesterol (190 mg/dl or higher)

      Statin Therapy

      Type 2 diabetes, 40-75 years old

      • A certain chance (7. 5% or higher) of having a heart attack or stroke within the next 10 years, and 40-75 years old.
      • In some cases, your doctor may recommend a statin even if you do not fit into the above groups. Your doctor will look at your overall health and other factors to determine if you are at high enough risk to benefit from a statin. Based on the guidelines, these could include:
      • Family history of premature heart attack or stroke
      • Lifetime risk of ASCVD

      Personal history of CHD risk

      • HS-CRP ≧ 2mg/L
      • Other specific inspection results (CAC, ABI scoring)
      • If you have had a heart attack, a stroke, or another type of ASCVD, you tend to be more useful if you can withstand status therapy. This may be more appropriate than taking multiple drugs to lower cholesterol.
      • For ASCVD patients over the age of 75 or patients (such as patients who have a history of organ transplantation), more moderate statin administration may be appropriate.
      • Before finding the best statin, you may need to try multiple statins.

      If you are on a statin, your care provider will need to find the dose that is right for you.

      • If you are 75 years old or older and have not yet suffered from heart attacks, stroke, or other ASCVDs, medical staff will consider whether the statin is suitable for you.
      • Not all patients can administer the optimal statin. If the known ASCVD, diabetes, or LDL cholesterol levels are very high (190 mg/dl or more) hig h-risk, no n-statusic drugs may be considered after paying attention to lifestyle improvement and statin therapy:

      The side effects of the statin do not reach the appropriate amount of administration, or cannot be taken at all.

      Since other drugs are taken, taking optimal doses is limited:

      Other cholesterol-lowering medications

      Transplantation plans to prevent rejection

      • Multiple medicines for treatment of HIV
      • Specific antibiotics such as erythromycin and clarislomycin, or specific oral antifungal drugs
        • As usual, it is important to consult a healthcare professional who is right for you.
        • Keeping LDL cholesterol low with the most optimal statin is strongly supported by clinical trials, but you cannot achieve a specific target value.
        • Take measures to reduce the risk factors of heart attacks, stroke, and other problem s-Healthy choices (healthy diets, exercise, healthy weight maintenance, smoking). If necessary, drug treatment can help you control risk factors.

        Report on side effect s-muscle pain and pain are often reported, but may not be due to status or not. If there is a problem, medical providers should be aware of managing side effects and in some cases changing them to another statin.

        What About Having Goals of Treatment?

        Take the medicine as instructed.

        Staying on Top of Your Risk

        • Received blood cholesterol and other tests recommended by the medical team. These tests can help you evaluate the status therapy and whether the dosage is right for you.
        • What are the danger factors for heart attacks and stroke? Am I doing the best prevention program to minimize this risk?
        • Is my cholesterol level higher enough to be genetic diseases?
        • What kind of lifestyle can be improved to maintain health and prevent problems?

        Questions to Ask

        • Should I take a statin?
        • How should I observe the progress?
        • What should I do if muscle pain or muscle weakness appears after starting the status?
        • What should I do if other symptoms appear after starting the status?
        • These Terms of Use and license agreements are between American College of Cardiology Foundation (hereinafter referred to as "ACCF") and customer and customer agent (hereinafter referred to as "customer"). Regardless of whether the version or web version is used, a legal contract (hereinafter referred to as "this" agreement ") is composed of the use of ASCVD Risk Estimator Plus (hereinafter referred to as" this product "). According to this product, the user is a specific content related to the ASCVD risk estimation contained in this product (hereinafter referred to as "this content".
        • By using this product, the user agrees all conditions stipulated in this Agreement and agree to be restrained. If you do not agree with the conditions of these Terms, you cannot continue using this product.
        • ACCF shall be able to change the clause of this agreement at any time without directly notification to the user. If these Terms are changed, ACCF will announce it in a place that is generally easy to see. If you do not agree with the conditions after the change, stop using this product immediately. After the notification, if the user continues to use this product, the user will be assumed to have accepted the changed terms and agreed to be restrained by it. These Terms are explicitly incorporated by referring to the rules or disclaimers that will be published or updated in this product or notified to users at any time.

        Groups that Benefit from Statin Therapy Infographic

        Common Cardiovascular Terms Alphabetical Glossary

        Links to Outside Resources

        Terms

        ASCVD Risk Estimator Plus Terms of Service and License Agreement

        ACCF allows you to end your access and/ or this product at any time. The user agrees that the end of the access to the product does not cause the responsibility or other duty to the ACCF user or third party related to the end. < Span> Is my cholesterol level higher enough to be a genetic disease?

        What kind of lifestyle can be improved to maintain health and prevent problems?

        Should I take a statin?

        Term and Termination

        How should I observe the progress?

        Intellectual Property Rights

        What should I do if muscle pain or muscle weakness appears after starting the status?

        Limitation of Liability

        What should I do if other symptoms appear after starting the status?

        Release of Liability

        These Terms of Use and license agreements are between American College of Cardiology Foundation (hereinafter referred to as "ACCF") and customer and customer agent (hereinafter referred to as "customer"). Regardless of whether the version or web version is used, a legal contract (hereinafter referred to as "this" agreement ") is composed of the use of ASCVD Risk Estimator Plus (hereinafter referred to as" this product "). According to this product, the user is a specific content related to the ASCVD risk estimation contained in this product (hereinafter referred to as "this content".

        Indemnification

        By using this product, the user agrees all conditions stipulated in this Agreement and agree to be restrained. If you do not agree with the conditions of these Terms, you cannot continue using this product.

        Disclaimer of Warranties

        ACCF shall be able to change the clause of this agreement at any time without directly notification to the user. If these Terms are changed, ACCF will announce it in a place that is generally easy to see. If you do not agree with the conditions after the change, stop using this product immediately. After the notification, if the user continues to use this product, the user will be assumed to have accepted the changed terms and agreed to be restrained by it. These Terms are explicitly incorporated by referring to the rules or disclaimers that will be published or updated in this product or notified to users at any time.

        ACCF allows you to end your access and/ or this product at any time. The user agrees that the end of the access to the product does not cause the responsibility or other duty to the ACCF user or third party related to the end. Is my cholesterol level higher enough to be genetic diseases?

        What kind of lifestyle can be improved to maintain health and prevent problems?

        Should I take a statin?

        How should I observe the progress?

        Force Majeure

        What should I do if muscle pain or muscle weakness appears after starting the status?

        No Assignment

        What should I do if other symptoms appear after starting the status?

        No Waiver

        These Terms of Use and license agreements are between American College of Cardiology Foundation (hereinafter referred to as "ACCF") and customer and customer agent (hereinafter referred to as "customer"). Regardless of whether the version or web version is used, a legal contract (hereinafter referred to as "this" agreement ") is composed of the use of ASCVD Risk Estimator Plus (hereinafter referred to as" this product "). According to this product, the user is a specific content related to the ASCVD risk estimation contained in this product (hereinafter referred to as "this content".

        Severability

        By using this product, the user agrees all conditions stipulated in this Agreement and agree to be restrained. If you do not agree with the conditions of these Terms, you cannot continue using this product.

        Governing Law

        ACCF shall be able to change the clause of this agreement at any time without directly notification to the user. If these Terms are changed, ACCF will announce it in a place that is generally easy to see. If you do not agree with the conditions after the change, stop using this product immediately. After such a notification, if the user continues to use this product, the user is assumed to have accepted the changed agreement and agreed to be restrained by it. These Terms are explicitly incorporated by referring to the rules or disclaimers that will be published or updated in this product or notified to users at any time.

        Certification

        ACCF allows you to end your access and/ or this product at any time. The user agrees that the end of the access to the product does not cause the responsibility or other duty to the ACCF user or third party related to the end.

        

        Elim Poon - Journalist, Creative Writer

        Last modified: 27.08.2024

        In our study, the ASCVD Risk Estimator Plus risk prediction model was used to predict year cardiovascular outcomes. The ASCVD Risk Estimator. Estimate patient's year ASCVD risk at an initial visit to establish a reference point. Forecast the potential impact of different interventions on patient. This peer-reviewed online calculator uses the Pooled Cohort Equations to estimate the year primary risk of ASCVD (atherosclerotic.